The top 100 stock
market authors
selected for publication
market authors
selected for publication
Simcere Pharmaceutical Group (SCR) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Simcere Pharmaceutical Group (SCR) by latest | most commented
- Emerging Market Biotechs: Multiple Under-Appreciated Stocks
- China Rising: CCG's May 18th Chinese Investment Conference
- China Biotech in Review: Deals, Approvals and More
- Simcere Pharma Follows Diversified Expansion Strategy
- China Biotech in Review: Deals and Earnings
- Simcere's Q1 Disappoints Investors
- Invention and Design Evident in China Biopharma
- Simcere Pharma Set to Produce Flu Drug in China
- China Biotech in Review: Cross Border Collaborations
- Simcere's Q4: Revenues Up, Earnings Down
- China Biopharma Continues to Expand Offerings
- Simcere Issues Net Income Warning for 2008
- China Bio in Review: More Fallout from Economic Crisis
- Investors Liked What They Saw in Simcere's Q3 Report
- China Bio Week-in-Review: Trials and Deals
- Simcere Shows Positive Data from Cancer Drug Trial
- Six Key Chinese Healthcare ADRs
- China ADRs: Mixed July
- Simcere’s Q2 Fails Expectations
- Global Investing, BRIC by BRIC: Part II
- China ADRs: Severe Loss in June
- China Biopharma Growth Metrics
- Simcere Granted SFDA Approval for Generic Antibiotic
- China Biopharma: What’s Not to Like?
- Simcere’s Q1: Revenue Increases 26%
- Biotech in Review: Investments in China Drug Development
- Simcere Buys Cancer Drug Company
- Simcere Books Solid 2007
- Simcere Pharmaceutical Gains on Strong Earnings
- China Biotech Week in Review: East-West Interdependence in 2007
- Biotech Week in Review: Cross Border China Pharma Activity
- Simcere Acquires New Cancer Drug; Misses on Q3 Revenue
- Reviewing A Good Week for China BioPharma Investment
- Simcere Pharma's Q3 Did No More Than Meet Expectations
- Simcere Reports Unimpressive Q3 Results
- It's More than Just Baidu: 51 Other Ways to Invest in China
- Recent Chinese IPOs Continue To Shine
- Best, Worst Performing Chinese ADRs YTD
- Simcere Invests Heavily in Rival Boda
- Biotech Week in Review: Sector Consolidation in China
- Recently Listed Simcere, Tongjitang Appear Attractively Priced
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
David Fry
-
2
Philip Davis
-
3
Tyler Durden
-
4
Bill Gross
-
5
Peter Schiff
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
